Milestone Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
MIST$0.74-3.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Shareholders’ Equity
Condensed Consolidated Statements of Shareholders’ Equit****y (Unaudited)
(in thousands of US dollars, except share data)
| | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Common Shares · · Pre-funded warrants · · · · · · · · · | |||||||||||||||||||
| · Numberof shares · Amount · Numberof warrants · Amount · Additionalpaid-incapital · Accumulateddeficit · Total | |||||||||||||||||||
| Balance as of June 30, 2023 | | 33,363,971 | | $260,169 | | 9,577,257 | | $48,459 | | $29,114 | | $(297,334) | | $40,408 | |||||
| Transactions in three-month period ended September 30, 2023 | | | | | | | | | | | | | | | | | | | |
| Net loss | | — | | | — | | — | | | — | | | — | | | (15,081) | | | (15,081) |
| Exercise of stock options | | 18,798 | | | 68 | | — | | | — | | | (28) | | | — | | | 40 |
| Share-based compensation | | — | | | — | | — | | | — | | | 2,872 | | | — | | | 2,872 |
| Employee stock purchase plan purchases | | 99,018 | | | 265 | | — | | | — | | | — | | | — | | | 265 |
| Balance as of September 30, 2023 | | 33,481,787 | | $260,502 | | 9,577,257 | | $48,459 | | $31,958 | | $(312,415) | | $28,504 | |||||
| | | | | | | | | | | | | | | | | | | | |
| Balance as of June 30, 2024 | | 53,269,565 | | $287,932 | | 12,910,590 | | $53,076 | | $36,713 | | $(345,743) | | $31,978 | |||||
| Transactions in three-month period ended September 30, 2024 | | | | | | | | | | | | | | | | | | | |
| Net loss | | — | | | — | | — | | | — | | | — | | | (9,439) | | | (9,439) |
| Share-based compensation | | — | | | — | | — | | | — | | | 1,399 | | | — | | | 1,399 |
| Employee stock purchase plan purchases | | 58,343 | | | 74 | | — | | | — | | | — | | | — | | | 74 |
| Balance as of September 30, 2024 | | 53,327,908 | | $288,006 | | 12,910,590 | | $53,076 | | $38,112 | | $(355,182) | | $24,012 | |||||
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| Balance as of December 31, 2022 | | 34,286,002 | | $273,900 | | 8,518,257 | | $34,352 | | $24,437 | | $(266,341) | | $66,348 | |||||
| Transactions in nine-month period ended September 30, 2023 | | | | | | | | | | | | | | | | | | | |
| Net loss | | — | | | — | | — | | | — | | | — | | | (46,074) | | | (46,074) |
| Exercise of stock options | | 112,779 | | | 324 | | — | | | — | | | (136) | | | — | | | 188 |
| Pre-funded warrants - Private Placement, net of issuance costs | | — | | | — | | 1,059,000 | | | 14,107 | | | — | | | — | | | 14,107 |
| Share-based compensation | | — | | | — | | — | | | — | | | 7,657 | | | — | | | 7,657 |
| Exchange of common shares | | (1,059,000) | | | (14,115) | | — | | | — | | | — | | | — | | | (14,115) |
| Employee stock purchase plan purchases | | 142,006 | | | 393 | | — | | | — | | | — | | | — | | | 393 |
| Balance as of September 30, 2023 | | 33,481,787 | | $260,502 | | 9,577,257 | | $48,459 | | $31,958 | | $(312,415) | | $28,504 | |||||
| | | | | | | | | | | | | | | | | | | | |
| Balance as of December 31, 2023 | | 33,483,111 | | $260,504 | | 9,577,257 | | $48,459 | | $33,834 | | $(326,026) | | $16,771 | |||||
| Transactions in nine-month period ended September 30, 2024 | | | | | | | | | | | | | | | | | | | |
| Net loss | | — | | | — | | — | | | — | | | — | | | (29,156) | | | (29,156) |
| Exercise of stock options | | 24,400 | | | 53 | | — | | | — | | | (24) | | | — | | | 29 |
| Pre-funded warrants, net of issuance costs | | — | | | — | | 3,333,333 | | | 4,617 | | | — | | | — | | | 4,617 |
| Share-based compensation | | — | | | — | | — | | | — | | | 4,302 | | | — | | | 4,302 |
| Issuance of common shares, net of issuance costs | | 19,666,667 | | | 27,258 | | — | | | — | | | — | | | — | | | 27,258 |
| Employee stock purchase plan purchases | | 153,730 | | | 191 | | — | | | — | | | — | | | — | | | 191 |
| Balance as of September 30, 2024 | | 53,327,908 | | $288,006 | | 12,910,590 | | $53,076 | | $38,112 | | $(355,182) | | $24,012 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.